Featured Research

from universities, journals, and other organizations

Breast Tumors In Mice Eradicated Using Cancer Vaccine

Date:
September 15, 2005
Source:
University of Pennsylvania School of Medicine
Summary:
A team from the University of Pennsylvania School of Medicine has shown that by using a cancer vaccine based on the bacterium Listeria monocytogenes, they can cure mice with established breast tumors. Using Listeria, the researchers, delivered the tumor-associated antigen HER-2/Neu to immune cells. HER-2/Neu is overexpressed in 20 to 40 percent of all breast cancers. These cells eventually enlist killer T cells to destroy the tumor cells that display the HER-2/Neu molecule.

Listeria inside a macrophage, an immune cell enlisted in the immune response.
Credit: Paul Neeson, PhD, University of Pennsylvania School of Medicine

"We found that we can stop the tumor from growing outto 100 days, at which time we stopped measuring since this is a longtime for experiments of this type," says Paterson. "The tumors stoppedgrowing or went completely away." The researchers published theirfindings in the September 15 issue of The Journal of Immunology.

"Theproblem that we encounter is that often by the time a patient presentswith cancer, they've developed immune tolerance to the tumor antigen,particularly when the antigen is expressed at low levels on normaltissue as with Her2/Neu," explains Paterson. "So how is the body tomount a strong enough immune reaction?"

In general, bacteria aregood at inducing both innate and adaptive immune responses, activatingsuch immune cells as macrophages, dendritic cells, and T cells. Thishelps jump-start the immune response to break tolerance.

But, whyListeria over other bacteria as a vehicle to deliver a tumor-associatedantigen? Because of Listeria's unusual life style. Normally, whenbacteria get taken up into an antigen-presenting cell, they areengulfed by a phagocytic vacuole where they get killed-whereupon theirproteins get broken down into smaller pieces (peptides) and attached toMHC Class 2 molecules. These egress to the cell surface, where theyexpand and activate helper T cells, which are enlisted into the immuneresponse.

But Listeria has evolved to escape from this vacuoleand survive inside the cytosol of antigen-presenting cells, where itcan replicate and grow, unlike other bacteria. So, although some of thebacteria are destroyed in the vacuole that feeds the MHC class IIpathway of antigen presentation with the induction of helper T cells,others survive by escaping into the cytosol of the cell. This isimportant because the antigen-processing pathway that feeds antigenicpeptides to the surface of the cell for recognition by killer T cellsis generated in this cellular compartment. "We reasoned that if wecould get Listeria to secrete a foreign protein into the interior ofthe cell, it would target that pathway and would elicit a strong killerT cell response, and we have shown that," says Paterson. "Listeria isalmost unique in the bacterial kingdom in doing this."

In thismodel, pieces of the very large HER-2/Neu molecule are broken up intolittle fragments and bound to the MHC Class 1 molecule within theantigen-presenting cell. This is what the killer T cell "sees" at thecell surface. These killer T cells, which are being produced in thespleen, where Listeria usually colonizes, seek out and destroy thetumor. This system ensures an increase in the production of killer Tcells that can recognize the HER-2/Neu pieces on the surface of thetumor cell. In addition, the Penn team helped the immune system alongby fusing the tumor antigen to a bacterial protein that seems toactivate antigen-presenting cells. They have found that by doing thisthe immune system now recognizes regions of the HER-2/neu molecule thatare not immunogenic when presented by other vaccine approaches.

Patersonfirst hit on the idea of using Listeria as a cancer vaccine vector overten years ago. "It took a while to dissect what elements of an immuneresponse were best able to cause the rejection of established tumors,"she says. "But in the last couple of years it has paid off and we arevery excited to see the technology finally being tested in cancerpatients. The dream of the cancer immunotherapist is to provide analternative and more humane way of controlling metastatic disease thancurrent chemotherapies."

The Listeria vector is currently beingprepared for a clinical trial targeting a tumor antigen associated withcervical cancer by Advaxis Inc., a cancer vaccine biotech company thathas licensed Penn patents on the use of Listeria monocytogenes as avaccine vector. Paterson is the scientific founder of Advaxis and Chairof the Scientific Advisory Board. The successful demonstration that theListeria vector technology can also be used with the HER-2/neu moleculepaves the way for applying this promising cancer vaccine approach tobreast cancer.

This research was funded by the Department ofDefense and the National Cancer Institute. Co-authors are Reshma Singhand Mary E. Dominiecki, both from Penn, as well as Elizabeth M. Jaffeefrom the Johns Hopkins University School of Medicine.


Story Source:

The above story is based on materials provided by University of Pennsylvania School of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University of Pennsylvania School of Medicine. "Breast Tumors In Mice Eradicated Using Cancer Vaccine." ScienceDaily. ScienceDaily, 15 September 2005. <www.sciencedaily.com/releases/2005/09/050915004756.htm>.
University of Pennsylvania School of Medicine. (2005, September 15). Breast Tumors In Mice Eradicated Using Cancer Vaccine. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2005/09/050915004756.htm
University of Pennsylvania School of Medicine. "Breast Tumors In Mice Eradicated Using Cancer Vaccine." ScienceDaily. www.sciencedaily.com/releases/2005/09/050915004756.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins